EXTENDED REPORT

Aptoptosis-derived membrane vesicles drive the cGAS–STING pathway and enhance type I IFN production in systemic lupus erythematosus

Yasuhiro Kato,1,2,3 JeongHoon Park,2,4 Hyota Takamatsu,1,2,3,5 Hachirou Konaka,1,2,3 Wataru Aoki,5,6 Syunsuke Aburaya,5,6 Mitsuysoshi Ueda,5,6 Masayuki Nishide,1,2,3 Shohei Koyama,1,2,3,5 Yoshitomo Hayama,1,2,3 Yuhei Kinehara,1,2 Toru Hirano,1,2 Yoshihito Shima,1,2 Masashi Narazaki,1,2 Atsushi Kumanogoh1,2,3,5

ABSTRACT

Objective Despite the importance of type I interferon (IFN-I) in systemic lupus erythematosus (SLE) pathogenesis, the mechanisms of IFN-I production have not been fully elucidated. Recognition of nucleic acids by DNA sensors induces IFN-I and interferon-stimulated genes (ISGs), but the involvement of cyclic guanosine monophosphate (GMP)–AMP synthase (cGAS) and stimulator of interferon genes (STING) in SLE remains unclear. We studied the role of the cGAS–STING pathway in the IFN-I-producing cascade driven by SLE serum.

Methods We collected sera from patients with SLE (n=64), patients with other autoimmune diseases (n=31) and healthy controls (n=35), and assayed them using a cell-based reporter system that enables highly sensitive and specific signalling pathway-dependent ISG induction.

Results IFN-I bioactivity and ISG-inducing activities of serum were higher in patients with SLE than in patients with other autoimmune diseases or healthy controls. ISG-inducing activity of SLE sera was significantly reduced in STING-knockout reporter cells, and STING-dependent ISG-inducing activity correlated with disease activity. Double-stranded DNA levels were elevated in SLE. Apoptosis-derived membrane vesicles (AdMVs) from SLE sera had high ISG-inducing activity, which was diminished in cGAS-knockout or STING-knockout reporter cells.

Conclusions AdMVs in SLE serum induce IFN-I production through activation of the cGAS–STING pathway. Thus, blockade of the cGAS–STING axis represents a promising therapeutic target for SLE. Moreover, our cell-based reporter system may be useful for stratifying patients with SLE with high ISG-inducing activity.

Although the exact cause of SLE remains unclear, type I interferon (IFN-I) plays important roles in its pathogenesis and progression. Serum IFN-I and expression of multiple IFN-I-stimulated genes (ISGs) in peripheral blood mononuclear cells (PBMCs) are elevated in SLE and associated with SLE disease activity.6,6 Also, clinical lupus occasionally occurs after treatment of chronic hepatitis with recombinant IFN-α.7 Furthermore, although SLE is heterogeneous, over 80% of patients exhibit a prevalent IFN signature.8 Clinical trials revealed that IFN-I-targeting therapies are more effective in patients with high ISG expression.9,10

Activation of pattern-recognition receptors (PRRs) is important for IFN-I production. Two major PRR signalling pathways recognise DNA: Toll-like receptor 9 (TLR9) and cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING).11,12 These DNA-sensing pathways are crucial for SLE onset. A recent genome-wide association study demonstrated that several alleles of genes related to nucleic acid degradation and IFN-I signalling are associated with the risk of SLE.13–17 In humans and mice, defective DNA degradation leads to excessive DNA and systemic inflammation via overproduction of IFN-I.18–21 Also, stimulation of TLR9 by double-stranded DNA (dsDNA) and immune complexes (ICs) from patients with SLE results in IFN-I overproduction.22,23 TLR9 is important in SLE pathogenesis, but other molecular mechanisms also contribute to IFN-I production.24,25 Given that cGAS and STING are involved in DNA recognition,26–28 the cGAS–STING pathway may play a role in SLE.

Although DNaseII−/− mice die during development due to overproduction of IFN-I, both Sting−/− and cGAS−/− DNaseII−/− prevent embryonic lethality and reduce lupus-like manifestation, despite intact production of autoantibodies.29,30 In three prime repair exonuclease 1 (Trex1)-deficient mice, development of lupus-like symptoms is ameliorated by knockout of cGAS or STING.30,31 In humans, gain-of-function mutation in STING causes SLE-like disease.32,33 Furthermore, PBMCs of SLE express higher levels of cGAS, and approximately 15% of patients with SLE express detectable levels of cyclic GMP–AMP (cGAMP) in their PBMCs.34 However, the role of the cGAS–STING pathway in SLE pathogenesis remains

INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease in which pathogenic autoantibodies are produced against nucleic acids and their interacting proteins, resulting in inflammation and tissue damage. SLE is characterised by flares and remissions, with multiple organ damage ranging from mild rash to severe nephritis, and has a poor prognosis.1,2
unclear. To address this issue, we used patient samples and a cell-based reporter system that enables highly sensitive measurement of serum IFN-I bioactivity and ISG-inducing activity.

**MATERIALS AND METHODS**

**Clinical samples**

Subjects were Japanese patients admitted to the Department of Clinical Immunology, Osaka University, from 2012 to 2017. SLE (n=75), systemic sclerosis (SSc) (n=24) and primary Sjögren syndrome (SjS) (n=11) were diagnosed based on the 1997 American College of Rheumatology (ACR) revised criteria for the classification of SLE, the 1980 ACR criteria for the classification of SSc and the American-European Consensus Group 2002 criteria for SjS respectively. Healthy control (HC) samples were obtained from 31 volunteer donors. Eleven patients were excluded from the study according to the criteria described in online supplementary figure S1. Disease activity of SLE was assessed according to Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.

**Reporter cell lines**

THP1-Blue ISG (THP1-ISG), HEK-Blue IFN-α/β, THP1-Dual, THP1-Dual-KOSTING and THP1-Dual-KOcGAS cells were purchased from InvivoGen. Knockout lines THP1-ISG-KOSTING and THP1-ISG-KOIFNAR2 were generated from THP1-ISG using the CRISPR-Cas9 gene-editing system. Briefly, THP1-ISG was lentivirally transduced with lentiGuide-Puro (Addgene) fused with sgRNA. Monoclonal knockout cells were confirmed by western blotting and DNA sequencing.

**Cell-based reporter assay**

For measurement of IFN-I, HEK-Blue IFN-α/β was incubated with 20% serum. For measurement of ISG-inducing activity, phorbol 12-myristate 13-acetate (PMA)-treated THP1-ISG was cultured with 20% serum. Secreted embryonic alkaline phosphatase (SEAP) in supernatant was detected with QUANTI-Blue (Invivogen) and quantified by optical density at 620 nm. PBMCs from healthy donors were isolated with Ficoll-Paque Plus (GE Healthcare). PBMCs were incubated with 20% serum. Secreted embryonic alkaline phosphatase in supernatant was detected with QUANTI-Blue (Invitrogen). For measurement of IFN-I, HEK-Blue IFN-α/β, which produces SEAP in response to IFN-I (see online supplementary figure S1), was used.

**Extracellular measurement of dsDNA**

Extracellular dsDNA in serum or AdMVs was extracted using DNA Extractor SP Kit (Wako) and quantified using the Quant-iT dsDNA Assay Kit (Invitrogen).

**Statistical analysis**

All statistical analyses were conducted using JMP Pro V.12.2.0. Non-parametric Mann-Whitney U test was used for comparisons between two groups and Steel test was used for comparisons between more than three groups. P values <0.05 were considered statistically significant. Correlations between clinical parameters and ISG-inducing activity or IFN-I level were determined using Spearman’s rank correlation coefficient (ρ).

**RESULTS**

**Elevated IFN-I bioactivity in SLE serum**

In the Osaka University Hospital database, we searched for patients with SLE who satisfied the ACR revised criteria for classification of SLE. Sixty-four patients with SLE were enrolled in this study (see online supplementary figure S1). The clinical characteristics of patients and HCs are summarised in table 1. For comparison, 24 patients with SSc and 11 patients with SjS were also enrolled (see online supplementary table S1). To measure the bioactivity of IFN-I in serum, we used HEK-Blue IFN-α/β, which produces SEAP in response to IFN-I (see online supplementary figure S2A,B). IFN-I bioactivity was significantly higher in SLE sera than in sera from HC or patients with other connective tissue diseases (figure 1A).

**Induction of ISGs by SLE serum**

Progression of SLE is associated with upregulation of IFN-I and ISGs. Using THP1-ISG cells, we investigated whether SLE serum could promote further IFN-I production. These cells secrete SEAP in response to various ISG-inducing stimuli, including IFN-I, 2’3’-cGAMP, cyclic-diAMP (c-diAMP) and lipopolysaccharide (see online supplementary figure S2C,D). ISG-inducing activity was considerably higher in SLE sera than in sera from HC, SjS or SSc (figure 1B). Although ISGs are upregulated in the PBMCs of SLE, SjS and SSc, only SLE sera had significant ISG-inducing activity.

**IFN-I-independent ISG-inducing activity in SLE serum**

We next examined the contribution of IFN-I in ISG induction by blocking IFN-I with antibodies against IFN-α, IFN-β and
Basic and translational research

IFNAR2 (see online supplementary figure S3A). Although ISG induction was reduced by IFN-I signalling blockade, ISG-inducing activity still remained in SLE sera (figure 1C). To confirm this, we established IFNAR2-knockout THP1-ISG (THP1-ISG-KOIFNAR2) (see online supplementary figure S3B,C). Even in these cells, ISG-inducing activity was observed with SLE sera (see online supplementary figure S3D). We then evaluated the effect of SLE serum in human PBMCs. PBMCs from healthy donors did not produce additional IFN-I on stimulation with recombinant IFN-α/β (see online supplementary figure S3E). However, SLE sera induced significant ISG production in the PBMCs (figure 1D). Thus, ISG induction by SLE serum is driven by not only IFN-I but also other factors.

Association of ISG-inducing activity and TLR9
Loss of tolerance to nucleic acids and impaired DNA degradation are thought to be important in SLE pathogenesis.18 19 We purified and quantified extracellular DNA in sera and found that the amount of dsDNA was higher in SLE than in HC (figure 2A). Because TLR9 is a major dsDNA sensor,11 we investigated its involvement in SLE serum-mediated inflammation. THP1-ISG was unresponsive to agonists of TLR9 (figure 2B and online supplementary figure S4A), TLR7 and TLR8 (see online supplementary figure S4B). To assess the involvement of TLR9, we used HEK-Blue TLR9 (see online supplementary figure S4C,D). Some SLE sera activated HEK-Blue TLR9, but this activation did not correlate with the levels of IFN-I-independent ISG-inducing activity (figure 2C). Because TLR7 plays important roles in SLE pathogenesis,43 we examined the involvement of TLR7 and TLR8 (see online supplementary figure S4E,F). Although sera from several patients activated TLR7 and TLR8, the levels of activation did not correlate with IFN-I-independent ISG-inducing activity (see online supplementary figure S5A,B). Therefore, pathways other than TLR7, TLR8 or TLR9 mediated the ISG induction by SLE sera.

Figure 1 High IFN-I levels and ISG-inducing activities of SLE serum. (A) IFN-I bioactivities in sera. IFN-I bioactivities in SLE (n=54), SjS (n=11), SSc (n=24) and HC (n=24) were measured using HEK-Blue IFN-α/β reporter cells. (B) ISG-inducing activities in sera. Levels of ISG-inducing activity in SLE (n=60), SjS (n=11), SSc (n=24) and HC (n=24) were measured using THP1-ISG reporter cells. (C) ISG-inducing activity of SLE sera with IFN-I signalling blockade. THP1-ISG reporter cells were stimulated with sera from SLE (n=48) and HC (n=7) in the absence (IFN blockade −) or presence (IFN blockade +) of antibody cocktail (anti-IFN-α, anti-IFN-β and anti-IFNAR2). (D) IFN-I production in PBMCs induced by SLE sera. Recombinant human IFN-α(rhIFNα), SLE sera (n=12) or HC sera (n=5) were incubated for 24 hours with or without PBMCs from healthy donors. Levels of IFN-I in the culture supernatants were measured using HEK-Blue IFN-α/β reporter cells. PBMC-derived IFN-I levels were calculated by subtracting the IFN-I levels in PBMC-absent medium from the IFN-I levels in PBMC-present medium. The box chart indicates the 75th percentile (upper), median (middle) and 25th percentile (lower) (A–C). Overall statistical differences between SLE and other groups were evaluated by Steel test (A,B). Overall differences between the groups were evaluated by Mann-Whitney U test (C,D). HC, healthy control; IFN-I, type I interferon; ISG, IFN-I-stimulated genes; PBMC, peripheral blood mononuclear cells; SjS, Sjögren syndrome; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
Induction of ISGs by SLE serum via the STING pathway

The cGAS–STING pathway is another dsDNA sensor. To evaluate its contribution in SLE serum-mediated inflammation, we established STING-knockout THP1-ISG (ISG-KOSTING) (figure 3A). When these cells were stimulated with SLE sera, most samples exhibited reduced ISG-inducing activity (figure 3B), suggesting that ISG induction was at least partially dependent on STING pathway. STING-dependent ISG-inducing activity correlated with the IFN-I-independent ISG-inducing activity of SLE sera (figure 3C). Thus, activation of the STING pathway may be responsible for high IFN-I levels in SLE.

Activation of the cGAS–STING pathway by AdMVs in SLE serum

The STING agonist 2′,3′-cGAMP is synthesised by cGAS after dsDNA recognition. Hence, we investigate whether STING agonists were present in serum. Serum was analysed using triple quadrupole-type liquid Chromatography-Mass spectrometry (LCMS), which was capable of detecting 2′,3′-cGAMP and c-diAMP at concentrations as low as 100 fmol/mL (see online supplementary figure S6A). Eight samples with STING-dependent ISG induction were analysed; however, neither 2′,3′-cGAMP nor c-diAMP was detected (see online supplementary figure S6B). Consistent with this, ISG induction by SLE sera was not reduced even after cGAMP degradation with ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) (see online supplementary figure S6C). Thus, 2′,3′-cGAMP and c-diAMP were not present in SLE serum.

Next, we examined the involvement of dsDNA in ISG induction. However, ISG-inducing activity was not diminished by DNase I treatment (figure 4A). We also investigated the involvement of ICs, but neither anti-FcγRI (CD64) antibody nor non-specific polyclonal IgG suppressed ISG induction by SLE sera (see online supplementary figure S7A,B). Hence, we examined the role of extracellular membrane vesicles in serum. To this end, we isolated AdMVs from serum (see online supplementary figure S6D).
Basic and translational research

S8A–C). dsDNA was contained in AdMVs and protected from DNase I degradation (figure 4B,C). We then cultured PBMCs with the isolated AdMVs and measured IFN-I with cGAS–STING pathway.

Clinical features and ISG-inducing activity of SLE serum

Finally, we investigated the relationship between clinical features and the IFN-I bioactivity or ISG-inducing activity of SLE serum. As shown in figure 5A, the ISG-inducing activity of SLE sera correlated with the SLEDAI-2K score. Likewise, the IFN-I bioactivity, STING-dependent ISG-inducing activity and IFN-I-independent ISG-inducing activity also individually correlated with SLEDAI-2K (see online supplementary figure S10A). Patients with high ISG-inducing activity manifested lymphocytopenia, low serum C4 levels and high anti-dsDNA antibody titres (figure 5B–D and online supplementary figure S10B). The presence of lupus nephritis did not affect the levels of IFN-I or ISG-inducing activity (figure 5E and online supplementary figure S10C). These results suggested that the ISG-inducing activity of serum measured by reporter cells could be a useful biomarker for assessing SLE disease activity.

DISCUSSION

In this study, we showed that SLE serum induced ISGs, in part, through cGAS–STING pathway. In addition, we found that dsDNA was present in SLE serum, and that AdMVs in SLE serum facilitated ISG expression via the cGAS–STING pathway. Using...
a cell-based reporter system, we demonstrated that the levels of IFN-I bioactivity and ISG-inducing activity were associated with SLE disease activity. Together, our results elucidate a possible pathological mechanism of SLE in which AdMVs drive IFN-I production through the cGAS–STING pathway (see online supplementary figure S11).

TLRs are major receptors in innate immunity that recognise nucleic acids. Endosomal TLRs are important in pathogenic overexpression of IFN-I and ISGs in SLE. However, the identification of cGAS and STING implicated their roles in the onset of SLE. In murine models, the role of cGAS–STING seems to be controversial. For instance, Sting−/− MRL/Faslo mice exhibit more severe disease phenotype, while deficiency of cGAS or STING in DNaseI−/− mice results in reduced lupus-like symptoms. In humans, constitutively active mutations of STING are associated with SLE-like diseases. Although these studies suggest that the cGAS–STING pathway contributes to lupus pathophysiology, it remains unclear whether cell intrinsic or extrinsic factors activate this pathway. Recent studies reported that cGAMP is present in SLE-derived PBMCs, and that cGAMP is released into the extracellular space upon stimulation. We studied this phenomenon using ultra-high-sensitivity LCMS, but detected neither 2’3’-cGAMP nor c-diAMP in the SLE sera. However these experiments were limited by the small sample size. Here, we showed that the amount of dsDNA in SLE sera was high. SLE serum-induced ISG expression was mediated by cGAS and STING, suggesting that cell-extrinsic dsDNA activated the cGAS–STING pathway. Consistent with our findings, oxidised mitochondrial DNA released by NETosis can drive the cGAS–STING pathway.
modification. Therefore, further investigation of these features is necessary.

One possible delivery mechanism for extracellular dsDNA into the cytosol is engulfment of ICs.53 We assessed the contribution of ICs in SLE serum-mediated ISG induction by blocking FcγR. However, blocking engulfment of ICs did not affect ISG induction, suggesting that ICs did not mediate ISG-inducing activity in our experimental setting.

We observed that AdMVs isolated from SLE serum contain dsDNA and induce ISG expression. Nucleic acids present in extracellular vesicles are protected from enzymatic degradation.54 In accordance with this, dsDNA in AdMVs was resistant to DNase I and SLE serum-mediated ISG induction was unchanged by DNase I treatment. Consistent with our findings, SLE-derived AdMVs can activate immune cells, resulting in enhanced IFN-I secretion.55–57 In most studies, AdMVs are harvested from culture supernatant of PBMCs in which apoptosis has been artificially induced by ultraviolet radiation. By contrast, using a cell-based reporter system, we directly showed that AdMVs in SLE sera induced IFN-I production. Additionally, we demonstrated that AdMV-mediated ISG induction was cGAS-dependent and STING-dependent. In regard to the difference of AdMVs from SLE and those from HC, there are several possibilities: increased amount of AdMVs in SLE serum, increased amount of dsDNA in AdMVs, unique property of dsDNA in AdMVs, the nature of the membrane of AdMVs which may allow efficient engulfment by scavenger cells and so on. In our results, the amount of dsDNA in AdMVs was higher in SLE than that in HC. However, we could not address other possibilities. Further studies are needed to clarify the characteristics of AdMVs and their association with clinical manifestations.

Human TLR9 is highly expressed in certain immune cells, but at low levels in monocytes, macrophages and non-haematopoietic cells.58 59 Nonetheless, high ISG expression has been observed in these cell types in patients with SLE. Several studies showed that TLR9 expression is downregulated in the PBMCs of SLE.16 60 Additionally, the TLR9 response of plasmacytoid dendritic cells is transient and decreases with continuous exposure to ligands,24 25 suggesting that TLR9-independent mediators are important for chronic and durable IFN-I production. The THP1 cells we used were unresponsive to agonists of TLR7, TLR8 and TLR9. Therefore, THP1 is suitable for evaluating the involvement of cytosolic nucleic acid sensors other than TLRs. Various cytosolic DNA sensors (eg, TLR9, cGAS, AIM2 and others) recognise dsDNA,11 12 but functionally dominant sensors may depend on the cell type and inflammatory condition. In cells expressing low levels of TLR9, the cGAS–STING pathway may be the major sensor of extracellular DNA that ultimately leads to sustained IFN-I production in SLE.

In some patients with SLE, the dependence of IFN-I production on the cGAS–STING pathway was partial, suggesting the involvement of other factors. Cytosolic RNA can activate...
IFN-I production. Some SLE sera activated reporter cells for TLR7 and TLR8, suggesting that RNA may also be present in SLE serum. It is possible that RNA-sensing pathways might be involved in the SLE serum-induced IFN-I production. Therefore, further investigation of the roles of RNA sensors in SLE is warranted.

In terms of clinical indicators, we demonstrated that both IFN-I and ISG-induced activity were higher in sera of SLE than other autoimmune diseases. The levels of IFN-I and ISG induc-tion correlated with SLE disease activity. Stratification of patients with SLE based on molecular profiles is important because the clinical symptoms and gene expression profiles are heterogeneous. The expression levels of ISGs are thought to be useful biomarkers for SLE stratification. Accordingly, treatments that target IFN-I have been shown to be effective in patients with high ISG expression. However, the current method for evaluating ISG expression is still complicated, and the sensitivity of ELISA is insufficient. Because our cell-based reporter system enables easy and highly sensitive evaluation of both IFN-I and ISG induction, it may be useful for stratifying patients with SLE.

It should be noted that the number of samples in this pilot study might be insufficient to definitively determine the clinical significance of serum ISG-inducing activity. Also, the possibility of sampling bias cannot be excluded. Moreover, several issues still require clarification: whether the ISG-inducing activity of serum depends on the clinical features and whether measurement of ISG-inducing activity is useful for evaluating or predicting clinical progression and efficacy of treatment. Multicentre and prospective studies are needed to answer these questions.

Collectively, we have shown that SLE serum significantly induces ISG expression and IFN-I production. In mechanistic terms, AdMVs facilitate the IFN-I-producing cascade in a cGAS-STING-dependent manner. Accordingly, we propose the following model of SLE pathophysiology. First, defective clearance of apoptotic cells produces AdMVs containing dsDNA, which in turn induces IFN-I production via the cGAS–STING pathway. Next, IFN-I activates immune responses that lead to tissue damage in various organs, resulting in further generation of AdMVs, triggering a positive-feedback loop of IFN-I production and further tissue damage (see online supplementary figure S11). In this context, it may be promising to target the cGAS–STING pathway for SLE treatment, and our cell-based reporter system may be useful for stratifying patients with SLE with high ISG-inducing activity.

Acknowledgements The authors appreciate the patients and healthy volunteers who participated in this research. We also thank the members of the Department of Clinical Immunology for collection of blood samples. We are grateful to Dr Hiroyuki Miyoshi (Keio University, Japan), the RIKEN BioResource Center (RIKEN BRC) and Dr Feng Zhang (MIT, USA) for providing the materials.

Contributors HT and YKa designed the project. YKa and Jp performed most experiments. YKa analysed the data. HT, YKa and JP wrote the manuscript. SA and WA performed the MS analysis. HK assisted with the experiments. SK, YH and YKi participated in the discussions. MN, TH, YS and MNA collected clinical samples and provided critical suggestions. MU provided critical collaborative suggestions regarding the MS analysis. AK oversaw the study.

Funding This study was supported in part by a research grant from JSPS KAKENHI (15K09950, to HT); a Core Research for Evolutionary Science and Technology (CREST) grant from the Japan Science and Technology Agency (JST) (JPMJCR1662, to HT and MU); the Naito Foundation (to HT); the Center of Innovation Program (COI-STREAM) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) (to AK); Japan Agency for Medical Research and Development (AMED)-CREST grant (15652227, to AK); and MEXT Grant-in-Aid (14525001, to AK).

Competing interests None declared.

Patient consent Obtained.

Ethics approval Enrolment of all participants was approved by the institutional review boards of Osaka University. Informed consent was obtained from all subjects in accordance with the Declaration of Helsinki and with approval of the ethical review board of Osaka University (no 12456-3 and 11122-4).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are available from the corresponding author upon request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers 2016;2:16039.
2. Lifsits-levkova I, Murphy G, Isegben D. Systemic lupus erythematosus. The Lancet 2014;384:1878–88.
3. Crow MK, Offerlev M, Kirou KA. Targeting of type I interferon in systemic autoimmune diseases. Transl Res 2015;165:296–305.
4. Hooks JI, Moustopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;310:5–8.
5. Preble OT, Black RJ, Friedman RM, et al. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982;216:429–31.
6. Hua J, Kirou K, Lee C, et al. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906–16.
7. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-α. Autoimmunity 2003;36:511–8.
8. Bandhure R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016;165:551–65.
9. Khamashita M, Mirlir JT, Werth VP, et al. Sifalimumab, an interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909–16.
10. Funke R, Khamashita M, Mirlir JT, et al. Anifrolumab, an interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376–86.
11. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805–20.
12. Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytoplasmic DNA sensing. Nat Immunol 2016;17:1142–9.
13. Bentham J, Morris DL, Graham DSC, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet 2015;47:1457–64.
14. Alarcón-Riquelme ME, Ziegler JT, Molineros J, et al. Genome-wide association study in an American ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis Rheumatol 2016;68:932–43.
15. Wang CM, Chang SW, Wu YJ, Yi Y, et al. Genetic variations in toll-like receptors (TLRs 3/7/8) are associated with systemic lupus erythematosus in a Taiwanese population. Sci Rep 2014;4:3792.
16. Laska MJ, Trolldborg A, Hansen B, et al. Polymorphisms within toll-like receptors are associated with systemic lupus erythematosus in a cohort of Danish females. Rheumatology 2014;53:48–55.
17. Kawakami A, Furukawa H, Kondo Y, et al. TLR7 single-nucleotide polymorphisms in the 3′ untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res Ther 2011;13:R41.
Basic and translational research

Kawane K, Ohtani M, Miwa K, et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. *Nature* 2006;443:998–1002.

Stetson DB, Ko JS, Heidmann T, et al. Trex1 prevents cell-intrinsic initiation of autoimmunity. *Cell* 2008;134:587–98.

Ramanantoni G, Kohlihasa J, Hertzberg C, et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. *Arthritis Rheum* 2010;62:1469–77.

Sisirak V, Sally B, D’Agati V, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. *Cell* 2016;166:88–101.

Means TK, Lutz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. *J Clin Invest* 2005;115:407–17.

Renault J, Riggs JM, Karnell JL, et al. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. *Nat Immunol* 2016;17:196–203.

Murayama G, Furusawa N, Chiba A, et al. Enhanced IFN-α production is associated with increased TRIF retention in the lysosomes of palmitoyltransferase cells in systemic lupus erythematosus. *Arthritis Res Ther* 2010;12(Suppl 1):S6.

Wu M, Assassi S. The role of type 1 interferon in systemic sclerosis. *Front Immunol* 2013;4:266.

Kono DH, Baccala R, Theofilopoulos AN. TLRs and interferons: a central paradigm in autoimmunity. *Curr Opin Immunol* 2013;25:720–7.

Li L, Yin Q, Kuss P, et al. Hydrolysis of 2’-5’-cGAMP by ENPP1 and design of nonhydrolyzable analogs. *Nat Chem Biol* 2014;10:1043–8.

Nickerson KM, Christensen SR, Shupe J, et al. TLR9 regulates TRIF- and MyD88-dependent autoantibody production and disease in a murine model of lupus. *J Immunol* 2010;184:1840–8.

Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). *Expert Opin Drug Saf* 2017;16:411–9.

Sharma S, Campbell AM, Chan J, et al. Suppression of systemic autoimmunity by the innate immune adaptor STING. *Proc Natl Acad Sci U S A* 2015;112:E710–7.

Ablasser A, Schmid-Burgk JL, Hemmerling T, et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP.* Nature* 2013;503:530–4.

Gentili M, Koval J, Tkach M, et al. Transmission of innate immune signaling by neutrophils drive type I interferon production in human lupus. *J Exp Med* 2016;213:697–713.

Mahajan A, Herrmann M, Muñoz LE. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE.* Front Immunol* 2016;7:35.

Buzas EI, György B, Nagy G, et al. Emerging role of extracellular vesicles in inflammatory diseases. *Nat Rev Rheumatol* 2014;10:356–64.

Niessen A, Heyder P, Krienke S, et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. *Immunity* 2012;36:120–31.

Liu Y, Jesus AA, Marrero B, et al. Expression of Cyclic GMP-AMP synthase in patients with systemic lupus erythematosus correlates with disease activity. *Arthritis Res* 2013;25:720–7.

Baggiolini M. Induction of type I IFN is a physiological immune reaction to apoptotic cell-derived membrane microparticles. *J Immunol* 2012;189:2443–53.

Dieker J, Tel J, Pieterse E, et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. *Arthritis Rheumatol* 2016;68:462–72.

Schiller M, Paricina M, Heyder P, et al. Induction of type I IFN is a physiological immune reaction to apoptotic cell-derived membrane microparticles. *J Immunol* 2012;189:1747–56.

Vitali C, Bombardieri S, Jonsson R, et al. Emerging role of extracellular vesicles in systemic lupus erythematosus. *Nat Chem Biol* 2014;10:453–61.

Cella T, Fairhurst AM. Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. *Front Pharmacol* 2014;5:265.

Zarro S, Arias M, Riaño F, et al. Response to GDN-CpG by B Cells from patients with systemic lupus erythematosus correlates with disease activity. *Lupus* 2009;18:718–26.

Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* 2014;343:84–7.

Yao Y, Higgs BW, Richman L, et al. Use of type I interferon-inducible miRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IgG4 antibody, in systemic lupus erythematosus. *Arthritis Res Ther* 2010;12(Suppl 1):S6.